Scleroderma screening: Difference between revisions
Jump to navigation
Jump to search
| Line 15: | Line 15: | ||
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3]. | According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3]. | ||
==Screening== | ==Screening== | ||
There is insufficient evidence to recommend routine screening for scleroderma, however screening is recommended for pulmonary arterial hypertension and malignancy in scleroderma patients | There is insufficient evidence to recommend routine screening for scleroderma, however screening is recommended for pulmonary arterial hypertension and malignancy in scleroderma patients: | ||
*According to the ACCF/AHA expert consensus document, screening for pulmonary arterial hypertension (PAH) by transthoracic echocardiogram (TTE) and pulmonary function tests (PFTs) is recommended every year among patients with scleroderma.<ref name="pmid19389575">{{cite journal |vauthors=McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J |title=ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association |journal=J. Am. Coll. Cardiol. |volume=53 |issue=17 |pages=1573–619 |date=April 2009 |pmid=19389575 |doi=10.1016/j.jacc.2009.01.004 |url=}}</ref><ref name="pmid24022584">{{cite journal |vauthors=Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV |title=Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension |journal=Arthritis Rheum. |volume=65 |issue=12 |pages=3194–201 |date=December 2013 |pmid=24022584 |pmc=3883571 |doi=10.1002/art.38172 |url=}}</ref> | *According to the ACCF/AHA expert consensus document, screening for pulmonary arterial hypertension (PAH) by transthoracic echocardiogram (TTE) and pulmonary function tests (PFTs) is recommended every year among patients with scleroderma.<ref name="pmid19389575">{{cite journal |vauthors=McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J |title=ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association |journal=J. Am. Coll. Cardiol. |volume=53 |issue=17 |pages=1573–619 |date=April 2009 |pmid=19389575 |doi=10.1016/j.jacc.2009.01.004 |url=}}</ref><ref name="pmid24022584">{{cite journal |vauthors=Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV |title=Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension |journal=Arthritis Rheum. |volume=65 |issue=12 |pages=3194–201 |date=December 2013 |pmid=24022584 |pmc=3883571 |doi=10.1002/art.38172 |url=}}</ref> | ||
*Enhanced screening for malignancy is recommended in patients at high risk for cancer-associated scleroderma.<ref name="pmid26352736">{{cite journal |vauthors=Shah AA, Casciola-Rosen L |title=Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening |journal=Curr Opin Rheumatol |volume=27 |issue=6 |pages=563–70 |date=November 2015 |pmid=26352736 |pmc=4643720 |doi=10.1097/BOR.0000000000000222 |url=}}</ref> | *Enhanced screening for malignancy is recommended in patients at high risk for cancer-associated scleroderma.<ref name="pmid26352736">{{cite journal |vauthors=Shah AA, Casciola-Rosen L |title=Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening |journal=Curr Opin Rheumatol |volume=27 |issue=6 |pages=563–70 |date=November 2015 |pmid=26352736 |pmc=4643720 |doi=10.1097/BOR.0000000000000222 |url=}}</ref> | ||
Revision as of 20:13, 5 April 2018
|
Scleroderma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Scleroderma screening On the Web |
|
American Roentgen Ray Society Images of Scleroderma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
There is insufficient evidence to recommend routine screening for scleroderma, however screening is recommended for pulmonary arterial hypertension and malignancy in scleroderma patients:
- According to the ACCF/AHA expert consensus document, screening for pulmonary arterial hypertension (PAH) by transthoracic echocardiogram (TTE) and pulmonary function tests (PFTs) is recommended every year among patients with scleroderma.[1][2]
- Enhanced screening for malignancy is recommended in patients at high risk for cancer-associated scleroderma.[3]
References
- ↑ McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J (April 2009). "ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association". J. Am. Coll. Cardiol. 53 (17): 1573–619. doi:10.1016/j.jacc.2009.01.004. PMID 19389575.
- ↑ Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV (December 2013). "Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension". Arthritis Rheum. 65 (12): 3194–201. doi:10.1002/art.38172. PMC 3883571. PMID 24022584.
- ↑ Shah AA, Casciola-Rosen L (November 2015). "Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening". Curr Opin Rheumatol. 27 (6): 563–70. doi:10.1097/BOR.0000000000000222. PMC 4643720. PMID 26352736.